{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:07Z","timestamp":1791315487265,"version":"4.3.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22208155"],"award-info":[{"award-number":["22208155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017287","name":"Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA0917800"],"award-info":[{"award-number":["2024YFA0917800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bioorg.2025.109345","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:44:42Z","timestamp":1765179882000},"page":"109345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives"],"prefix":"10.1016","volume":"168","author":[{"given":"Tao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJuan","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zherui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguo","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6330","key":"10.1016\/j.bioorg.2025.109345_bb0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109345_bb0010","doi-asserted-by":"crossref","first-page":"12138","DOI":"10.1073\/pnas.192453199","article-title":"The structural basis for the transition from Ras-GTP to Ras-GDP","volume":"99","author":"Hall","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"25","key":"10.1016\/j.bioorg.2025.109345_bb0020","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109345_bb0025","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109345_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS (G12C) somatic mutations across race, sex, and Cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109345_bb0035","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109345_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.sbi.2021.06.013","article-title":"Stopping the beating heart of cancer: KRAS reviewed","volume":"71","author":"Herdeis","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"7477","key":"10.1016\/j.bioorg.2025.109345_bb0045","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"7781","key":"10.1016\/j.bioorg.2025.109345_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109345_bb0060","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of Cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109345_bb0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109345_bb0085","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109345_bb0090","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109345_bb0095","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109345_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109345_bb0105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109345_bb0110","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.109345_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113006","article-title":"Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway","volume":"211","author":"Korzeniecki","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109345_bb0120","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/ijbs.88779","article-title":"Impact of KRAS mutation on the tumor microenvironment in colorectal cancer","volume":"20","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2025.109345_bb0125","doi-asserted-by":"crossref","first-page":"1509173","DOI":"10.3389\/fimmu.2025.1509173","article-title":"Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 Axis drives immune suppression and immune therapy resistance in colorectal Cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS oncogenic signaling extends beyond Cancer cells to orchestrate the microenvironment","volume":"78","author":"Dias Carvalho","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0145","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41467-021-21736-w","article-title":"KRAS drives immune evasion in a genetic model of pancreatic cancer","volume":"12","author":"Ischenko","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109345_bb0150","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2025.109345_bb0155","doi-asserted-by":"crossref","first-page":"1223433","DOI":"10.3389\/fimmu.2023.1223433","article-title":"Small molecular inhibitors for KRAS-mutant cancers","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109345_bb0165","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109345_bb0170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of Cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109345_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910219","article-title":"Highlights on the role of KRAS mutations in reshaping the microenvironment of pancreatic adenocarcinoma","volume":"22","author":"Hafezi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109345_bb0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/13543776.2022.2032648","article-title":"Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019-2021)","volume":"32","author":"Xu","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109345_bb0185","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.molmed.2025.03.007","article-title":"Targeting the yin and Yang of KRAS(G12C)","volume":"31","author":"Adamopoulos","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109345_bb0190","doi-asserted-by":"crossref","first-page":"16173","DOI":"10.1021\/acs.jmedchem.2c01438","article-title":"JDQ443, a structurally novel, Pyrazole-based, covalent inhibitor of KRAS(G12C) for the treatment of solid tumors","volume":"65","author":"Lorthiois","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109345_bb0195","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1021\/acs.jmedchem.2c00369","article-title":"Discovery of AZD4625, a covalent allosteric inhibitor of the mutant GTPase KRAS(G12C)","volume":"65","author":"Kettle","year":"2022","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109345_bb0200","doi-asserted-by":"crossref","first-page":"9147","DOI":"10.1021\/acs.jmedchem.3c00746","article-title":"Discovery of AZD4747, a potent and selective inhibitor of mutant GTPase KRAS(G12C) with demonstrable CNS penetration","volume":"66","author":"Kettle","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109345_bb0205","article-title":"Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer","volume":"131 Suppl 1(Suppl 1)","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.109345_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117391","article-title":"Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRAS(G12C) inhibitors for the treatment of cancer","volume":"289","author":"Shang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109345_bb0215","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1021\/acs.jmedchem.4c00572","article-title":"Discovery of MK-1084: an orally bioavailable and low-dose KRAS(G12C) inhibitor","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0220","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1021\/acs.jmedchem.4c03071","article-title":"Identification of structurally novel KRAS(G12C) inhibitors through covalent DNA-encoded library screening","volume":"68","author":"Huang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0225","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/acs.jmedchem.4c02939","article-title":"Design, structure optimization, and preclinical characterization of JAB-21822, a covalent inhibitor of KRAS(G12C)","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0230","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/2159-8290.CD-24-1885","article-title":"Beyond first-generation KRAS inhibitors: BBO-8520 tests the dual mechanism hypothesis","volume":"15","author":"Zhou","year":"2025","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-025-02364-0","article-title":"Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/17460441.2022.2029842","article-title":"Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design","volume":"17","author":"Haider","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"22","key":"10.1016\/j.bioorg.2025.109345_bb0245","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1021\/acs.jmedchem.3c01724","article-title":"Design, synthesis, and pharmacological evaluation of multisubstituted Pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRAS(G12D) inhibitors","volume":"66","author":"Xiao","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109345_bb0250","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41591-022-02008-6","article-title":"The KRAS(G12D) inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis","volume":"28","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0255","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109345_bb0260","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109345_bb0265","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ccell.2024.06.005","article-title":"HRS-4642: the next piece of the puzzle to keep KRAS in check","volume":"42","author":"Flores-G\u00f3mez","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109345_bb0270","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1021\/acs.jmedchem.4c02662","article-title":"Discovery of INCB159020, an orally bioavailable KRAS G12D inhibitor","volume":"68","author":"Ye","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7968","key":"10.1016\/j.bioorg.2025.109345_bb0275","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","article-title":"ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma","volume":"24","author":"Bandi","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109345_bb0285","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"issue":"35","key":"10.1016\/j.bioorg.2025.109345_bb0290","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1021\/jacs.2c05377","article-title":"Chemoselective covalent modification of K-Ras(G12R) with a small molecule electrophile","volume":"144","author":"Zhang","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109345_bb0295","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41589-022-01065-9","article-title":"Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)","volume":"18","author":"Zhang","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0300","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109345_bb0305","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.109345_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115857","article-title":"Discovery of highly potent and selective KRAS(G12C) degraders by VHL-recruiting PROTACs for the treatment of tumors with KRAS(G12C)-mutation","volume":"261","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109345_bb0315","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRAS(G12D)","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109345_bb0320","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and characterization of RP03707: a highly potent and selective KRAS(G12D) PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem"},{"issue":"6715","key":"10.1016\/j.bioorg.2025.109345_bb0330","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109345_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031550","article-title":"Challenges in discovering drugs that target the protein-protein interactions of disordered proteins","volume":"23","author":"Ol\u00e1h","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"45","key":"10.1016\/j.bioorg.2025.109345_bb0345","doi-asserted-by":"crossref","first-page":"16314","DOI":"10.1002\/anie.201910124","article-title":"Bifunctional small-molecule ligands of K-Ras induce its association with Immunophilin proteins","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"6659","key":"10.1016\/j.bioorg.2025.109345_bb0350","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109345_bb0355","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of Elironrasib (RMC-6291), a potent and orally bioavailable, RAS(ON) G12C-selective, covalent Tricomplex inhibitor for the treatment of patients with RAS G12C-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109345_bb0360","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109345_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116579","article-title":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","volume":"275","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109345_bb0370","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109345_bb0375","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MOH.0000000000000345","article-title":"Role of SHP2 in hematopoiesis and leukemogenesis","volume":"24","author":"Pandey","year":"2017","journal-title":"Curr. Opin. Hematol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109345_bb0380","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J. Cell. Mol. Med."},{"issue":"20","key":"10.1016\/j.bioorg.2025.109345_bb0385","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in Cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2025.109345_bb0390","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of Cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109345_bb0395","doi-asserted-by":"crossref","first-page":"13158","DOI":"10.1021\/acs.jmedchem.2c00986","article-title":"Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0400","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109345_bb0405","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109345_bb0410","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human Cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109345_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109345_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109345_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177428","article-title":"Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: past, present, and future","volume":"996","author":"Dong","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109345_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8080281","article-title":"Targeting mutant KRAS in pancreatic Cancer: futile or promising?","volume":"8","author":"Nollmann","year":"2020","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109345_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124325","article-title":"Targeting KRAS mutant non-small-cell lung Cancer: past, present and future","volume":"21","author":"Uras","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0440","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in colorectal Cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109345_bb0445","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal Cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109345_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109345_bb0455","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109345_bb0460","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109345_bb0465","doi-asserted-by":"crossref","first-page":"1412435","DOI":"10.3389\/fonc.2024.1412435","article-title":"Assessment of KRAS(G12C) inhibitors for colorectal cancer","volume":"14","author":"Piazza","year":"2024","journal-title":"Front. Oncol."},{"issue":"7999","key":"10.1016\/j.bioorg.2025.109345_bb0470","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41586-023-06954-0","article-title":"The energetic and allosteric landscape for KRAS inhibition","volume":"626","author":"Weng","year":"2024","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bioorg.2025.109345_bb0475","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.celrep.2020.03.021","article-title":"Defining and targeting adaptations to oncogenic KRAS(G12C) inhibition using quantitative temporal proteomics","volume":"30","author":"Santana-Codina","year":"2020","journal-title":"Cell Rep."},{"issue":"8013","key":"10.1016\/j.bioorg.2025.109345_bb0480","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:06:04Z","timestamp":1768399564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":96,"alternative-id":["S0045206825012258"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109345","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109345"}}